ISCO International and Abside Networks Deliver Advanced 5G Anti-Jamming Resiliency
High-performance 5G radio network solution with integrated interference and jamming cancellation technology now available
Abside now offers a high-performance 5G RAN solution that incorporates ISCO's field-proven interference detection and cancellation technology, delivering a more resilient, hardened wireless network protected from jammers.
ISCO's patented IMC software technology leverages advanced digital signal processing to automatically detect, identify, and cancel radio frequency (RF) interference – whether from intentional signal jamming, random narrowband and wideband sources, or tropospheric ducting. With this capability embedded directly into Abside's architecture the combined solution enhances network reliability, spectrum efficiency, and operational continuity by protecting the 5G network against rogue jammers and unexpected interference.
This collaboration aligns with the broader industry shift toward intelligent, software-defined RAN architectures, supporting the mission of the AI-RAN Alliance to enable AI-native, interoperable, and resilient wireless networks.
"Starting with Abside's advanced 5G radio platform, the integration of ISCO's interference management technology delivers an industry-first solution capable of natively detecting and canceling harmful jammers and interference," said
"Integrating ISCO's interference mitigation capabilities into our platform strengthens our ability to deliver secure and dependable 5G infrastructure for mission-critical applications," said
About ISCO International
ISCO International is the leading
About Abside Networks
Abside Networks is a
View original content to download multimedia:https://www.prnewswire.com/news-releases/isco-international-and-abside-networks-deliver-advanced-5g-anti-jamming-resiliency-302754926.html
SOURCE ISCO International
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Aker Solutions ASA: Second-quarter and half-year results 2026
- FDA approves Leqembi Iqlik® (lecanemab-irmb) subcutaneous injection as a starting dose for early Alzheimer's disease
- Interim report: January - June 2026
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share